48236
Shanghai Desano Bio-pharmaceutical Co., Ltd.
Jul 22, 2024
China
East Asia and the Pacific
Jun 4, 2024
B - Limited
Active
Oct 25, 2025
Regional Industry - MAS Asia & Pac
other
Approved : Jun 4, 2024
Signed : Jun 8, 2024
Invested : Dec 16, 2024
other
Shanghai Desano Bio-Pharmaceutical Co., Ltd (“Desano”, “the Company”) is a leading Active Pharmaceutical Ingredients (“API”) and Finished Dosage Formulation (“FDF”) manufacturer in China, focusing on producing antiretroviral (“ARV”) drugs to address the global public health challenge of Human Immunodeficiency Viruses (“HIV”).
The proposed investment is a US$100 million equivalent A loan to the Company’s subsidiaries to support: (i) the construction of a new API/FDF manufacturing facility in Bangalore, India, and (ii) the expansion of an existing API manufacturing facility in Jiangxi Province, China (a frontier region), for ARV drugs targeting low- and middle-income countries (the “Project”). The Project intends to play a key role in reducing the treatment cost of HIV patients globally and enhancing the resilience of pharmaceutical supply chain through localized production.
For Inquiries About the Project, Contact
For Inquiries and Comments About IFC, Contact
Local Access of Project Documentation
Environmental documents will be made accessible to locally affected communities.